Optimi Health (OPTI) Registration filing summary

Company overview and business model

• Operates as a Canadian GMP-compliant pharmaceutical manufacturer specializing in MDMA and psilocybin from botanical sources, licensed by Health Canada for controlled substances.

• Owns two 10,000 sq. ft. production facilities in Princeton, BC, with Drug Establishment Licence (DEL) and Dealer's Licence (DL) enabling legal manufacture and export.

• Products are available in Australia (for PTSD and TRD) and Canada (via Special Access Program); expansion targeted for Israel and the U.S. pending regulatory changes.

• Vertically integrated operations allow for rapid scaling, cost control, and quality assurance.

• Winding down nutraceutical business to focus on pharmaceutical-grade manufacturing.

Financial performance and metrics

• Fiscal year ended September 30, 2025: revenue C$426,301 (US$306,097), net loss C$3,712,031 (US$2,665,349).

• Three months ended December 31, 2025: revenue C$232,700, net loss C$1,553,975.

• Accumulated deficit as of December 31, 2025: C$27.2 million (US$20.0 million).

• Cash and cash equivalents as of December 31, 2025: C$491,750.

• Ongoing operating losses and negative cash flow; company notes substantial doubt about ability to continue as a going concern without additional financing.

Use of proceeds and capital allocation

• Net proceeds from IPO (estimated US$12.2 million) allocated as: 28.7% for scaling production/distribution, 18.0% for market entry to Israel and U.S. and sales growth, 53.3% for working capital and operating expenses.

• Funds expected to support scaling and market entry for 12 months; additional capital will be needed for U.S. entry beyond that period.

• Management has broad discretion over use of proceeds.